In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine
- PMID: 15365033
- PMCID: PMC516298
- DOI: 10.1128/JCM.42.9.4319-4320.2004
In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine
Abstract
Thirty isolates of the yeast form of Sporothrix schenckii were evaluated for in vitro susceptibility to itraconazole and terbinafine by the recommended NCCLS modified technique (M27-A2). The MICs of itraconazole obtained oscillated between 0.062 and 4.0 microg/ml, and those of terbinafine oscillated between 0.007 and 0.50 microg/ml; therefore, terbinafine showed greater in vitro activity.
References
-
- Araújo, T., A. C. Marques, and F. Kerdel. 2001. Sporotrichosis. Int. J. Dermatol. 40:737-742. - PubMed
-
- Barros, M. B. L., T. M. P. Schubach, M. C. G. Galhardo, A. O. Schubach, P. C. F. Monteiro, R. S. Reis, R. M. Z. Oliveira, M. S. Lazera, T. C. Maya, T. C. M. Blanco, K. B. F. Marzochi, B. Wanke, and A. C. F. Valle. 2001. Sporotrichosis: an emergent zoonosis in Rio de Janeiro. Mem. Inst. Oswaldo Cruz 96:777-779. - PubMed
-
- Casali, A. K., and J. S. Hamdan. 1997. Effect of three azole derivatives on the lipids of different strains of Sporothrix schenckii. Can. J. Microbiol. 43:1197-1202. - PubMed
-
- Chapman, S. W., P. Pappas, C. Kauffman, E. B. Smith, R. Dietze, N. Tiraboschi-Foss, A. Restrepo, A. B. Bustamante, C. Opper, S. Emady-Azar, and R. Bakshi. 2004. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day−1) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 47:62-68. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
